Table 3 Combined clinicopathologic analysis according to the various criteria
Characteristics | Amplification | GCN gain | 2013 ASCO/CAP guideline | ||||||
|---|---|---|---|---|---|---|---|---|---|
Negative | Positive | P | CN< 4 | 4 ≤CN | P | Negative | Equivocal or positive | P | |
Location | 0.403 | 0.241 | 0.213 | ||||||
Right colon | 79 (84.9%) | 14 (15.1%) | 69 (74.2%) | 24 (25.8%) | 67 (72.0%) | 26 (28.0%) | |||
Left colon | 100 (78.7%) | 27 (21.3%) | 81 (63.8%) | 46 (36.2%) | 77 (60.6%) | 50 (39.4%) | |||
Rectum | 89 (78.1%) | 25 (21.9%) | 75 (65.8%) | 39 (34.2%) | 74 (64.9%) | 40 (35.1%) | |||
pTNM stage | 0.708 | 0.124 | 0.257 | ||||||
I–III | 218 (79.9%) | 55 (20.1%) | 189 (69.2%) | 84 (30.8%) | 182 (66.7%) | 91 (33.3%) | |||
IV | 50 (82.0%) | 11 (18.0%) | 36 (59.0%) | 25 (41.0%) | 36 (59.0%) | 25 (41.0%) | |||
MSI status (n = 323) | 0.097 | 0.004 | 0.002 | ||||||
MSS/MSI-L | 235 (79.4%) | 61 (20.6%) | 194 (65.5%) | 102 (34.5%) | 188 (63.5%) | 108 (36.5%) | |||
MSI-H | 25 (92.6%) | 2 (7.4%) | 25 (92.6%) | 2 (7.4%) | 25 (92.6%) | 2 (7.4%) | |||